Patient data, antibodies, clinical findings.

Patient data, antibodies, clinical findings.</p

Results of whole-body PET/MRI.

Results of whole-body PET/MRI.</p

Results of cerebral PET/MRI.

Results of cerebral PET/MRI.</p

Sequence parameters for the diagnostic MR sequences used in PET/MRI.

Sequence parameters for the diagnostic MR sequences used in PET/MRI.</p

¹⁸F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis - Fig 2

75-year old patient with left sided enlargement of the hippocampus on T1 (A) and dull FLAIR-hyperintensity (B). Corresponding glucose hypermetabolism of the left hippocampus and amygdala can be detected on FDG-PET (C) and fusion with FLAIRw (D).</p

¹⁸F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis - Fig 4

59-year old patient with suspicious subscapular lesions with isointense signal on T2w (A), intense inhomogeneous contrast enhancement (B), no diffusion restriction (C) and mild tracer uptake with SUVmax of 3.2 (D).</p

¹⁸F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis - Fig 1

21-year old female patient with swelling and FLAIR hyperintensity of the left amygdala (A, B). PET shows corresponding glucose hypometabolism (C, D).</p

¹⁸F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis - Fig 3

75-year old patient with circumscribed thickening of the rectal wall and dull contrast enhancement (A), with a distinct diffusion restriction on the ADC-MAP (B). PET shows an intense semicircular tracer uptake with SUVmax of 8.8 (C, D). Final histopathological diagnosis was a rectal cancer.</p

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Stud

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study

Supplementary Data from Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Stud